Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa.

Publisher: BioMed Central Country of Publication: England NLM ID: 100966978 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2156 (Electronic) Linking ISSN: 14712156 NLM ISO Abbreviation: BMC Genet Subsets: MEDLINE

Original Publication: London : BioMed Central, [2000-

Genetic Variation* ; Genetics, Population*; Cytochrome P-450 CYP3A/*genetics; Africa ; Alleles ; Humans ; Phenotype

Background: Cytochrome P450 3A5 (CYP3A5) is an enzyme involved in the metabolism of many therapeutic drugs. CYP3A5 expression levels vary between individuals and populations, and this contributes to adverse clinical outcomes. Variable expression is largely attributed to four alleles, CYP3A5*1 (expresser allele); CYP3A5*3 (rs776746), CYP3A5*6 (rs10264272) and CYP3A5*7 (rs41303343) (low/non-expresser alleles). Little is known about CYP3A5 variability in Africa, a region with considerable genetic diversity. Here we used a multi-disciplinary approach to characterize CYP3A5 variation in geographically and ethnically diverse populations from in and around Africa, and infer the evolutionary processes that have shaped patterns of diversity in this gene. We genotyped 2538 individuals from 36 diverse populations in and around Africa for common low/non-expresser CYP3A5 alleles, and re-sequenced the CYP3A5 gene in five Ethiopian ethnic groups. We estimated the ages of low/non-expresser CYP3A5 alleles using a linked microsatellite and assuming a step-wise mutation model of evolution. Finally, we examined a hypothesis that CYP3A5 is important in salt retention adaptation by performing correlations with ecological data relating to aridity for the present day, 10,000 and 50,000 years ago.
Results: We estimate that ~43% of individuals within our African dataset express CYP3A5, which is lower than previous independent estimates for the region. We found significant intra-African variability in CYP3A5 expression phenotypes. Within Africa the highest frequencies of high-activity alleles were observed in equatorial and Niger-Congo speaking populations. Ethiopian allele frequencies were intermediate between those of other sub-Saharan African and non-African groups. Re-sequencing of CYP3A5 identified few additional variants likely to affect CYP3A5 expression. We estimate the ages of CYP3A5*3 as ~76,400 years and CYP3A5*6 as ~218,400 years. Finally we report that global CYP3A5 expression levels correlated significantly with aridity measures for 10,000 [Spearmann's Rho= -0.465, p=0.004] and 50,000 years ago [Spearmann's Rho= -0.379, p=0.02].
Conclusions: Significant intra-African diversity at the CYP3A5 gene is likely to contribute to multiple pharmacogenetic profiles across the continent. Significant correlations between CYP3A5 expression phenotypes and aridity data are consistent with a hypothesis that the enzyme is important in salt-retention adaptation.

PLoS Genet. 2005 Dec;1(6):e82. (PMID: 16429165)
Nat Biotechnol. 2012 Feb 08;30(2):126. (PMID: 22318022)
Science. 2008 Feb 22;319(5866):1100-4. (PMID: 18292342)
Am J Hum Genet. 2001 Apr;68(4):978-89. (PMID: 11254454)
Mol Biol Evol. 2004 May;21(5):936-44. (PMID: 15014171)
Mol Pharmacol. 2005 Sep;68(3):808-15. (PMID: 15955870)
Nat Genet. 2006 Nov;38(11):1251-60. (PMID: 17057719)
Arch Biochem Biophys. 1989 Nov 1;274(2):355-65. (PMID: 2802615)
Cancer Lett. 2005 Jan 10;217(1):61-72. (PMID: 15596297)
Nature. 2001 Feb 15;409(6822):758-60. (PMID: 11236971)
J Comput Biol. 1996 Winter;3(4):479-502. (PMID: 9018600)
Xenobiotica. 2006 Dec;36(12):1191-200. (PMID: 17162466)
Drug Metab Rev. 2009;41(2):89-295. (PMID: 19514967)
Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):928-32. (PMID: 14504207)
Ther Drug Monit. 2004 Apr;26(2):192-9. (PMID: 15228164)
Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. (PMID: 12406645)
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16057-62. (PMID: 19706453)
Clin Pharmacol Ther. 2007 May;81(5):708-12. (PMID: 17329995)
Bioinformatics. 2009 Jun 1;25(11):1451-2. (PMID: 19346325)
Genetics. 2000 Jul;155(3):1405-13. (PMID: 10880498)
Am J Hum Genet. 2002 May;70(5):1197-214. (PMID: 11910562)
Pharmacogenet Genomics. 2010 Nov;20(11):647-64. (PMID: 20881513)
Curr Biol. 2005 Mar 8;15(5):R159-60. (PMID: 15753023)
Clin Pharmacol Ther. 2005 May;77(5):373-87. (PMID: 15900284)
Philos Trans R Soc Lond B Biol Sci. 2011 Mar 27;366(1566):863-77. (PMID: 21320900)
Hum Genet. 2005 Aug;117(4):366-75. (PMID: 15928903)
Trends Genet. 2006 Aug;22(8):437-46. (PMID: 16808986)
Am J Hum Genet. 2003 Oct;73(4):768-79. (PMID: 13680527)
Hum Mutat. 2001 Aug;18(2):87-100. (PMID: 11462233)
Genetics. 2003 Jun;164(2):781-7. (PMID: 12807796)
Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):17-28. (PMID: 19968573)
Bioinformatics. 2005 Jul 1;21(13):2933-42. (PMID: 15860560)
Ann Hum Genet. 2005 May;69(Pt 3):275-87. (PMID: 15845032)
J Hypertens. 2006 May;24(5):923-9. (PMID: 16612255)
Ann Hum Genet. 2011 Mar;75(2):236-46. (PMID: 21309756)
Hum Genet. 1999 Dec;105(6):577-81. (PMID: 10647892)
PLoS Biol. 2006 Mar;4(3):e72. (PMID: 16494531)
J Biol Chem. 1989 Jun 25;264(18):10388-95. (PMID: 2732228)
J Appl Physiol (1985). 2003 Sep;95(3):1297-300. (PMID: 12754175)
Science. 2006 Jun 16;312(5780):1614-20. (PMID: 16778047)
Nat Genet. 2001 Apr;27(4):383-91. (PMID: 11279519)
Ther Drug Monit. 2010 Jun;32(3):346-52. (PMID: 20357698)
Pharmacogenomics J. 2011 Apr;11(2):130-7. (PMID: 20231858)
Evol Bioinform Online. 2007 Feb 23;1:47-50. (PMID: 19325852)
Lancet. 1998 Apr 18;351(9110):1208. (PMID: 9643720)
J Clin Pharm Ther. 2008 Feb;33(1):61-5. (PMID: 18211618)
Pharmacogenetics. 2003 Aug;13(8):461-72. (PMID: 12893984)
Pharmacogenetics. 2001 Dec;11(9):773-9. (PMID: 11740341)
Am J Hum Genet. 2004 Dec;75(6):1059-69. (PMID: 15492926)
Drug Metab Dispos. 2005 Jul;33(7):884-7. (PMID: 15833928)
Nat Genet. 2007 Jan;39(1):31-40. (PMID: 17159977)
Proc Biol Sci. 2012 Nov 7;279(1746):4305-21. (PMID: 22933370)
Am J Hum Genet. 2000 Feb;66(2):651-8. (PMID: 10677323)
J Comput Biol. 1997 Fall;4(3):311-23. (PMID: 9278062)
Am J Hum Genet. 2012 Jul 13;91(1):83-96. (PMID: 22726845)
Pharmacogenomics. 2009 Mar;10(3):477-87. (PMID: 19290795)
Lancet. 2002 Oct 12;360(9340):1155-62. (PMID: 12387968)
Am J Hum Genet. 2004 Nov;75(5):752-70. (PMID: 15457403)
Science. 2007 Nov 16;318(5853):1074-5. (PMID: 18006727)
Nat Methods. 2010 Apr;7(4):248-9. (PMID: 20354512)
Genetics. 1995 Jan;139(1):457-62. (PMID: 7705646)
Environ Health Perspect. 2009 Oct;117(10):1541-8. (PMID: 20019904)
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6723-7. (PMID: 7624310)
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15942-7. (PMID: 16243969)
Pharmacogenet Genomics. 2008 Oct;18(10):877-86. (PMID: 18794725)
Mol Pharmacol. 2002 Jul;62(1):162-72. (PMID: 12065767)
J Biol Chem. 2004 Sep 10;279(37):38379-85. (PMID: 15252010)
Am J Hum Genet. 2002 Nov;71(5):1082-111. (PMID: 12395296)
Lancet. 2010 May 1;375(9725):1497-8. (PMID: 20435212)
Gastroenterology. 2010 May;138(5):1653-4. (PMID: 20332044)
Gene. 2013 Jan 10;512(2):226-31. (PMID: 23107770)
Annu Rev Genomics Hum Genet. 2000;1:225-49. (PMID: 11701630)
Bioinformatics. 2004 Jan 22;20(2):289-90. (PMID: 14734327)
Mol Pharmacol. 1990 Aug;38(2):207-13. (PMID: 2385232)
Sci Am. 1979 Nov;241(5):98-100, 102, 108 passim. (PMID: 504979)
Pharmacogenomics J. 2006 Mar-Apr;6(2):105-14. (PMID: 16314882)
Hum Mol Genet. 2011 Feb 1;20(3):528-40. (PMID: 21081654)
Am J Hum Genet. 1998 May;62(5):1260-2. (PMID: 9545399)
Pharmacogenomics. 2009 Sep;10(9):1413-22. (PMID: 19761365)

United Kingdom Biotechnology and Biological Sciences Research Council

EC 1.14.14.1 (CYP3A5 protein, human)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)

Date Created: 20130507 Date Completed: 20131017 Latest Revision: 20220317

20240829

PMC3655848

10.1186/1471-2156-14-34

23641907